Elanco Animal Health: New Products To Support Growth

Redfox Capital Ideas 781 Followers Follow Summary I recommend a buy rating for Elanco Animal Health, driven by a strong new product cycle and robust clinic adoption. Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion for ELAN. Befrena offers another growth lever, with early demand exceeding expectations, though near-term contribution is limited by supply constraints. ELAN's valuation at ~21x forward PE appears reasonable, given accelerating earnings growth and margin improvement from product mix and productivity gains. Flashpop/DigitalVision via Getty Images Investment Summary My recommendation for Elanco Animal Health ( ELAN ) is a buy rating. The thesis is that ELAN is moving into a better product cycle, where Zenrelia is gaining clinic coverage and seeing a high reorder This article was written by Redfox Capital Ideas 781 Followers Follow I focus on long-term investments while incorporating short-term shorts to uncover alpha opportunities. My investment approach revolves around bottom-up analysis, delving into the fundamental strengths and weaknesses of individual companies. My investment duration is the medium to long-term. Ultimately, I aim to identify companies with solid fundamentals, sustainable competitive advantages, and growth potential. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.